… lower interindividual variability in the pharmacokinetic parameters, were observed following
… , high variability in the changes of pharmacokinetic parameters because of food intake was …

… , clinically significant alterations of liver parameters are rare with kinase inhibitors, and are
… To minimize complication risks, serum liver parameters should be assessed before initiating …

… kinase inhibitor (TKI) readministration to lung cancer patients is common owing to the few
options available. Impact of clinical … to understand the impact of clinical factors in such patients. …

… We speculated that several clinical parameters might differentially affect treatment response
… We therefore retrospectively analyzed the prognostic role of several clinical parameters in …

9021 Background: PLX4032 is an oral, highly selective inhibitor of oncogenic V600E BRAF
kinase currently in phase I trial. V600E BRAF mutation activates Raf/MEK/ERK pathway in …

… treated with tyrosine kinase inhibitors from two centers, … and other clinical and laboratory
parameters were assessed … patients with metastatic RCC using tyrosine kinase inhibitors. …

Background: Therapeutic response to oral targeted anticancer protein kinase inhibitors (PKIs)
varies widely between patients, with insufficient efficacy of some of them and …

… These enzymes all contain a highly conserved kinase domain, which includes binding sites
for small molecule tyrosine kinase inhibitors (TKIs). Imatinib was the first clinically useful TKI …

… BCR-ABL inhibitor, significant relationships between dose intensity and response and
toxicity were described in the approval report (n = 444), although PK parameters such as C min …

… tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous
are under investigation. These drugs are rationally designed to target specific tyrosine kinases …